AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35287430 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dose levels of COH04S1
Number of subjects: 56
Study 35287430 — intervention group
Group type: EXPERIMENTAL
Intervention: COH04S1 (any dose)
Number of subjects: 56
Study 33239044 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (1200 mg) administered intravenously < 12 h, on day 3 and on day 7 after ictus, with prophylactic antibiotics for 4 weeks.
Number of subjects: 40
Study 33239044 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 40
Study 36216769 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the APDS-Diversity and Inclusion Committee (APDS-DIC) in 2017
Number of subjects: 864
Study 36216769 — intervention group
Group type: COMPARATOR
Intervention: Before APDS-DIC inception (2008-2016)
Number of subjects: 864
Study 32829739 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised enteral feeding protocol with cerebro-somatic near-infrared spectroscopy
Number of subjects: 33
Study 32829739 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised enteral feeding protocol without cerebro-somatic near-infrared spectroscopy
Number of subjects: 33
Study 32829739 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (historical comparison)
Number of subjects: 33
Study 32829739 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding cohort
Number of subjects: 33
Study 36411708 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago exercise programme (OEP)
Number of subjects: 77
Study 36411708 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation training (Control)
Number of subjects: 77
Study 33745119 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple juice/preferred fluids
Number of subjects: 0
Study 33745119 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte maintenance solution
Number of subjects: 0
Study 35545122 — intervention group
Group type: COMPARATOR
Intervention: HDWL colonoscopy
Number of subjects: 800
Study 33019798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrodia-uncaria granules (5 to 10 g twice daily for 4 weeks)
Number of subjects: 251
Study 33019798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 to 10 g twice daily for 4 weeks)
Number of subjects: 251
Study 33019798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrodia-uncaria granules
Number of subjects: 251
Study 33019798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 33436683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 59
Study 33436683 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (ranibizumab + focal/grid short-pulse laser)
Number of subjects: 59
Study 32219478 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus, Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium bifidum) administered twice a day for 5 weeks
Number of subjects: 32
Study 32219478 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules administered twice a day for 5 weeks
Number of subjects: 32
Study 33309213 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw access channel group
Number of subjects: 40
Study 33309213 — intervention group
Group type: COMPARATOR
Intervention: Conventional crown group
Number of subjects: 40
Study 34825538 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga nidra
Number of subjects: 41
Study 34825538 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy for insomnia
Number of subjects: 41
Study 32894702 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical score tool based on preoperative predictors of tympanosclerosis identified through multivariate logistic regression analysis.
Number of subjects: 404
Study 32894702 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical score tool including independent factors such as female sex, frequency-specific air-bone gap at 250 Hz ≥ 45 dB HL, aditus ad antrum blockage, type I and II eardrum calcification, and history of otitis media ≥ 10 years.
Number of subjects: 404
Study 33989025 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin with Bevacizumab (GCB)
Number of subjects: 506
Study 33989025 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and Cisplatin with Placebo (GCP)
Number of subjects: 506
Study 32804188 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of regular, oral sustained-release morphine twice daily for 4 weeks (with possibility to increase to 3 times daily after 1 or 2 weeks)
Number of subjects: 124
Study 32804188 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of regular, oral sustained-release morphine
Number of subjects: 124
Study 32804188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 34648082 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with dose-dense paclitaxel (80 mg/m2 on days 1, 8, and 15), carboplatin (AUC 6.0 mg/mL × min. on day 1), and bevacizumab (15 mg/kg on day 1)
Number of subjects: 24
Study 34648082 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with dose-dense TC-bevacizumab therapy
Number of subjects: 24
Study 33975734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent caloric restriction
Number of subjects: 112
Study 33975734 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous caloric restriction
Number of subjects: 112
Study 33379931 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model predicting perceived differences based on individual AFs
Number of subjects: 0
Study 33379931 — intervention group
Group type: COMPARATOR
Intervention: Nonindividual HRTFs
Number of subjects: 0
Study 33402230 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol 5 mg plus promethazine 25 mg (HP)
Number of subjects: 100
Study 33402230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular chlorpromazine 100 mg plus haloperidol 5 mg plus promethazine 25 mg (HPC)
Number of subjects: 100
Study 32449896 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal flap
Number of subjects: 232
Study 32449896 — intervention group
Group type: COMPARATOR
Intervention: Control (no peritoneal flap)
Number of subjects: 232
Study 32863100 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS associated with vocal therapy
Number of subjects: 17
Study 32863100 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (electrodes placed, equipment off)
Number of subjects: 17
Study 32201120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients with eGFR<60mL/min per 1.73m2
Number of subjects: 3006
Study 32201120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients aged ≥65 years
Number of subjects: 3006
Study 32201120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive male patients
Number of subjects: 3006
Study 32201120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients with educational level <6 years
Number of subjects: 3006
Study 32201120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients who smoke
Number of subjects: 3006
Study 36109142 — intervention group
Group type: EXPERIMENTAL
Intervention: OKZ 64 mg once every 2 weeks (q2w)
Number of subjects: 368
Study 36109142 — intervention group
Group type: EXPERIMENTAL
Intervention: OKZ 64 mg once every 4 weeks (q4w)
Number of subjects: 368
Study 36109142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 368
Study 36109142 — intervention group
Group type: EXPERIMENTAL
Intervention: OKZ (both dosing regimens)
Number of subjects: 368
Study 33317342 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injector of insulin glargine (12-18 IU/day)
Number of subjects: 66
Study 33317342 — intervention group
Group type: COMPARATOR
Intervention: Insulin pen
Number of subjects: 66
Study 33232964 — intervention group
Group type: EXPERIMENTAL
Intervention: High vitamin K1 diet (4-week intervention of increased leafy green vegetable intake)
Number of subjects: 30
Study 35201920 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ (20 mg/day)
Number of subjects: 32
Study 35201920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32875670 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic manipulation
Number of subjects: 27
Study 32875670 — intervention group
Group type: COMPARATOR
Intervention: Conventional manipulation
Number of subjects: 27
Study 37770963 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise program
Number of subjects: 70
Study 37770963 — intervention group
Group type: COMPARATOR
Intervention: Digital booklet with self-care information
Number of subjects: 70
Study 33276115 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Number of subjects: 40
Study 33276115 — intervention group
Group type: COMPARATOR
Intervention: Tongue scraping (standard treatment)
Number of subjects: 40
Study 34698371 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg plus topical corticosteroids (TCS) as needed
Number of subjects: 277
Study 34698371 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus TCS as needed
Number of subjects: 277
Study 34698371 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab plus TCS
Number of subjects: 277
Study 34698371 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus TCS
Number of subjects: 277
Study 33175478 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewiring Updated Logistic Clinical SYNTAX score (LCSS)
Number of subjects: 512
Study 33175478 — intervention group
Group type: EXPERIMENTAL
Intervention: Postwiring Updated LCSS
Number of subjects: 512
Study 33175478 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewiring MI-SYNTAX score
Number of subjects: 512
Study 33175478 — intervention group
Group type: EXPERIMENTAL
Intervention: Postwiring MI-SYNTAX score
Number of subjects: 512
Study 33175478 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewiring Updated LCSS
Number of subjects: 512
Study 33175478 — intervention group
Group type: EXPERIMENTAL
Intervention: Four scores combined
Number of subjects: 512
Study 35731044 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk taste and smell administered together
Number of subjects: 0
Study 35731044 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk taste
Number of subjects: 0
Study 35731044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breast milk intervention)
Number of subjects: 0
Study 36359816 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 46
Study 36359816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 33111337 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP14012 (fexuprazan) 40 mg
Number of subjects: 30
Study 33111337 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP14012 (fexuprazan) 80 mg
Number of subjects: 30
Study 33111337 — intervention group
Group type: COMPARATOR
Intervention: DWP14012 (fexuprazan)
Number of subjects: 30
Study 37715688 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group with HPDs
Number of subjects: 50
Study 37715688 — intervention group
Group type: COMPARATOR
Intervention: Control group with HPDs
Number of subjects: 50
Study 37715688 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group in open ear condition
Number of subjects: 50
Study 37715688 — intervention group
Group type: COMPARATOR
Intervention: Control group in open ear condition
Number of subjects: 50
Study 33059496 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention combining savings- and lending-groups, entrepreneurial training, and other skills training
Number of subjects: 400
Study 33059496 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 400
Study 34104427 — intervention group
Group type: COMPARATOR
Intervention: Rice husk activated charcoal at 0%
Number of subjects: 24
Study 34104427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice husk activated charcoal at 1%
Number of subjects: 24
Study 34104427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice husk activated charcoal at 1.5%
Number of subjects: 24
Study 34104427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice husk activated charcoal at 2%
Number of subjects: 24
Study 34104427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice husk activated charcoal at 2.5%
Number of subjects: 24
Study 34104427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice husk activated charcoal at 3%
Number of subjects: 24
Study 36053867 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy for insomnia (dCBT-I)
Number of subjects: 208
Study 36053867 — intervention group
Group type: COMPARATOR
Intervention: Sleep education (Control)
Number of subjects: 208
Study 33397395 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg/day weekly)
Number of subjects: 0
Study 33397395 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 32513313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried fruit (3/4 cup/d mixed dried fruits: plums, figs, dates, and raisins)
Number of subjects: 55
Study 32513313 — intervention group
Group type: COMPARATOR
Intervention: Control (energy- and carbohydrate-matched snack)
Number of subjects: 55
Study 36018224 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 134
Study 33638769 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy plus partial splenic embolization (EP)
Number of subjects: 102
Study 33638769 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic treatment (E)
Number of subjects: 102
Study 35099442 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly designed graphic and text warning label 'poverty'
Number of subjects: 388
Study 35099442 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly designed label element 'dead person'
Number of subjects: 388
Study 35099442 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly designed label element 'look after family'
Number of subjects: 388
Study 34830530 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual supervised exercise program from 8–10 to 38–39 weeks of pregnancy
Number of subjects: 98
Study 36270625 — intervention group
Group type: EXPERIMENTAL
Intervention: Video- and sensor-based feedback
Number of subjects: 26
Study 36270625 — intervention group
Group type: COMPARATOR
Intervention: Control group (overall results and matched training load)
Number of subjects: 26
Study 33528102 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-friendly community initiative (BFCI) with standard maternal, infant and young child nutrition counselling, support from trained community health volunteers, health professionals and community and mother support groups
Number of subjects: 823
Study 33528102 — intervention group
Group type: COMPARATOR
Intervention: Standard counselling only (control group)
Number of subjects: 823
Study 33528102 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-friendly community initiative (BFCI)
Number of subjects: 823
Study 34356994 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RAGT) with physiotherapy
Number of subjects: 27
Study 34356994 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training without RAGT
Number of subjects: 27
Study 33571966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine 8.75 µg/h
Number of subjects: 60
Study 33571966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine 17.5 µg/h
Number of subjects: 60
Study 33571966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine 35 µg/h
Number of subjects: 60
Study 33571966 — intervention group
Group type: COMPARATOR
Intervention: Transdermal buprenorphine 8.75 µg/h and 17.5 µg/h
Number of subjects: 60
Study 35942633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban
Number of subjects: 180
Study 35942633 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tirofiban
Number of subjects: 180
Study 34333845 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol maleate 0.5% eye drops
Number of subjects: 16
Study 34333845 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 16
Study 33173695 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel combined with pressure garment (PG)
Number of subjects: 0
Study 33173695 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheet combined with pressure garment (PG)
Number of subjects: 0
Study 33173695 — intervention group
Group type: COMPARATOR
Intervention: Pressure garment (PG) alone
Number of subjects: 0
Study 33173695 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel and silicone gel sheet combined with PG
Number of subjects: 0
Study 34105213 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP)
Number of subjects: 597
Study 34105213 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (MET)
Number of subjects: 597
Study 34105081 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaired tetralogy of Fallot (rTOF) patients
Number of subjects: 49
Study 32982207 — intervention group
Group type: EXPERIMENTAL
Intervention: TIRE (advanced IMT electronic system PrO2)
Number of subjects: 0
Study 32982207 — intervention group
Group type: COMPARATOR
Intervention: Threshold loading IMT protocols
Number of subjects: 0
Study 32982207 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 0
Study 35172870 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized maxillary oral appliance (CMOA)
Number of subjects: 40
Study 35172870 — intervention group
Group type: COMPARATOR
Intervention: Mandibular advancement device (MAD)
Number of subjects: 40
Study 34016156 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention
Number of subjects: 33
Study 34016156 — intervention group
Group type: COMPARATOR
Intervention: Control (no hand hygiene intervention)
Number of subjects: 33
Study 32267031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with rose essence (0.2 ml)
Number of subjects: 160
Study 32267031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essence (0.2 ml)
Number of subjects: 160
Study 32267031 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 160
Study 32267031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cotton swab soaked in water)
Number of subjects: 160
Study 33881810 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty
Number of subjects: 0
Study 33881810 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial keratoplasty in 2 eyes
Number of subjects: 0
Study 33881810 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior densitometry
Number of subjects: 0
Study 33881810 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of pseudophakic bullous keratopathy
Number of subjects: 0
Study 34913883 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with Acceptance and Commitment Therapy (ExACT)
Number of subjects: 175
Study 34913883 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise programme alone (Control)
Number of subjects: 175
Study 33705985 — intervention group
Group type: EXPERIMENTAL
Intervention: HFRT (68 Gy in 25 fractions)
Number of subjects: 111
Study 33705985 — intervention group
Group type: COMPARATOR
Intervention: CFRT (78 Gy in 39 fractions)
Number of subjects: 111
Study 32161949 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-1473 20 mg
Number of subjects: 0
Study 32161949 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-1473 80 mg
Number of subjects: 0
Study 32161949 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-1473 270 mg
Number of subjects: 0
Study 32161949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34033301 — intervention group
Group type: EXPERIMENTAL
Intervention: Yacon flour (25g) with energy restricted diet
Number of subjects: 26
Study 34033301 — intervention group
Group type: COMPARATOR
Intervention: Control (no yacon flour) with energy restricted diet
Number of subjects: 26
Study 33320311 — intervention group
Group type: COMPARATOR
Intervention: PPE0 (no PPE)
Number of subjects: 30
Study 33320311 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE1 (improvised PPE)
Number of subjects: 30
Study 33320311 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE2 (off-the-shelf PPE)
Number of subjects: 30
Study 36152058 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warm-up (10 min cycling at 50% peak aerobic power)
Number of subjects: 11
Study 36152058 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no warm-up)
Number of subjects: 11
Study 36152058 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of day (morning vs. afternoon)
Number of subjects: 11
Study 36152058 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise recovery
Number of subjects: 11
Study 33998005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser resurfacing
Number of subjects: 40
Study 33998005 — intervention group
Group type: COMPARATOR
Intervention: Carboxytherapy
Number of subjects: 40
Study 33318068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (dose-adjusted 3, 7, or 14 mg)
Number of subjects: 382
Study 33318068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (initiated at 3 mg)
Number of subjects: 382
Study 33318068 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 382
Study 33318068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 382
Study 33318068 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 382
Study 33992267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN) plus manual therapy (MT)
Number of subjects: 40
Study 33992267 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy (MT) alone
Number of subjects: 40
Study 32265129 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) boost treatment of 19.5 to 21 Gy in 3 fractions (1 fraction per week)
Number of subjects: 100
Study 32265129 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) external beam radiotherapy (EBRT) boost treatment of 32 to 33 Gy in 15 to 16 fractions
Number of subjects: 100